News that the FDA approved Ibsrela to treat irritable bowel syndrome with constipation in adults and the American Society for Gastrointestinal Endoscopy’s updates to its guidelines for screening and surveillance of Barrett’s esophagus were among the top stories in gastroenterology last week.
Other top stories included study results that showed eosinophilic esophagitis symptoms recur quickly in patients who discontinue treatment.
FDA approves Ibsrela for IBS-C in adults
The FDA recently approved Ibsrela, a 50 mg, twice-daily oral therapy for irritable bowel syndrome with constipation in adults. Read more.
Gastrointestinal group releases updated screening, surveillance guidelines for Barrett’s esophagus
With the goal of improving morbidity and mortality related to esophageal adenocarcinoma, the American Society for Gastrointestinal Endoscopy’has released updated guidelines for the screening and surveillance of Barrett’s esophagus. Read more.
Eosinophilic esophagitis recurs rapidly after treatment discontinuation
Even after initial histologic response to induction therapy, eosinophilic esophagitis recurs rapidly in patients who discontinue treatment, regardless of the type of medication used, according to results of a randomized controlled trial. Read more.
Magnetic sphincter augmentation manages refractory GERD for up to 1 year
Patients with medically refractory GERD reported that magnetic sphincter augmentation sustained regurgitation control over 12 months, according to study results. Read more.
Genetic variants affect proton pump inhibitor response in pediatric eosinophilic esophagitis
Researchers from Nemours Children’s Health System identified gene variants that influence the efficacy of proton pump inhibitor therapy in children with eosinophilic esophagitis and said their findings could lead to new opportunities for personalized medicine. Read more.